Diagnostic performance of whole-body bone scintigraphy in combination with SPECT/CT for detection of bone metastases

2020 ◽  
Author(s):  
Yiqiu Zhang ◽  
Beilei Li ◽  
Bing Wu ◽  
Haojun Yu ◽  
Junyi Song ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Bone Scintigraphy ◽  
Diagnostic Performance ◽  
Whole Body ◽  
Body Bone

scholarly journals Bone Metabolism of the Patient with a Malignant Melanoma during the Entry Examination and the Check-up of Whole-body Bone Scintigraphy

2016 ◽  
Vol 117 (2-3) ◽  
pp. 129-134
Author(s):  
Jaroslav Weissensteiner ◽  
Eva Babušíková
Keyword(s):  
Malignant Melanoma ◽  
Bone Metastases ◽  
Bone Metabolism ◽  
Bone Scintigraphy ◽  
Type I Collagen ◽  
Tumour Marker ◽  
Whole Body ◽  
Type I ◽  
Negative Finding ◽  
Body Bone

Malignant melanoma is a malignancy located predominantly in the skin and the incidence of melanoma increases. We compared the markers of bone metabolism – osteocalcin (OC), beta-carboxyterminal cross-linked telopeptide of type I collagen (β-CrossLaps, β-CTx) and tumour marker – human epididymis protein 4 (HE4) in the serum with finding during the entry examination and the check-up of whole-body bone scintigraphy of the patient with a malignant melanoma. Serum concentrations of OC, β-CTx, HE4 were determined in 1 patient (female, age 64 years) with malignant melanoma and correlated with the presence of equivocal bone metastases detected by whole-body bone scintigraphy (the entry examination and check-up after 6 months). Concentrations of bone metabolism markers decreased during six months and we observed progress in bone metastases. The change of the markers levels during the entry examination and the check-up of the whole-body bone scintigraphy with equivocal finding of bone metastases could be a sign of a possible initiating progression of malignant melanoma despite a clinically negative finding that does not prove the progression of the disease.

scholarly journals Comparison of the Whole-Body Bone Scintigraphy with Levels of the Markers of Bone Metabolism in Serum of Patients with Malignant Melanoma

2015 ◽  
Vol 5 (1) ◽  
pp. 5-11 ◽  
Author(s):  
J. Weissensteiner ◽  
E. Babusikova
Keyword(s):  
Malignant Melanoma ◽  
Bone Metastases ◽  
Bone Metabolism ◽  
Bone Scintigraphy ◽  
Type I Collagen ◽  
Whole Body ◽  
Type I ◽  
Control Subjects ◽  
Body Bone ◽  
Physiological Value

Abstract Objective. The aim of this study was to evaluate serum levels of the biochemical markers of bone metabolism: osteocalcin (OC), beta-carboxyterminal cross-linked telopeptide of type I collagen (β-CTx) with the presence of bone metastases detected by whole-body bone scintigraphy in patients with malignant melanoma. Methods. We determined the markers of bone metabolism in the serum by electrochemiluminescent immunoanalysis in 14 patients with melanoma and in 10 persons without malignant disease (control subjects). All participants were examined by whole-body bone scintigraphy using hybrid scanner of type BrightView XCT. Results. The bone metastases by whole-body bone scintigraphy were in 5 cases, probably in 3 cases and 6 patients were without bone metastases from 14 patients (4 men, 10 women). The concentration of OC in patients was lower about 25.4% in comparison with control subjects. The concentration of OC in the serum was below physiological value in 6 patients and in 4 cases with bone metastases. The concentration of β-CTx was below physiological value in 3 patients and in 2 cases with bone metastases. Conclusion. We observed lower concentration of osteocalcin in patients with malignant melanoma compared to control subjects and the lowest ostecalcin concentration was observed in patients with bone metastases. We did not observe changes in the concentration of beta-carboxyterminal cross-linked telopeptide of type I collagen compared neither to control subjects nor between patients with or without bone metastases.

Advantages and limitations of whole-body bone marrow MRI using turbo-STIR sequences in comparison to planar bone scans

2000 ◽  
Vol 39 (06) ◽  
pp. 174-179 ◽  
Author(s):  
N. Manthey ◽  
F. Berger ◽  
H. Sommer ◽  
T. Pfluger ◽  
K. Hahn ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Metastases ◽  
Bone Scintigraphy ◽  
The Body ◽  
Whole Body ◽  
Advantages And Disadvantages ◽  
Slice Orientation ◽  
Mri Protocol ◽  
Bone Scans ◽  
Body Bone

SummaryAt modern MRI tomographs the whole body can be screened for bone marrow metastases within 45 min. Aim of this study was to evaluate the diagnostic advantages and disadvantages of a whole-body bone marrow MRI protocol using Turbo Short Tau Inversion Recovery [STIR] sequences in comparison to planar bone scintigraphy (SZ). Patients and methods: In order to screen for bone metastases within two weeks SZ and whole-body MRI with Turbo-STIR-sequences were performed in 20 patients with known breast cancer. For further evaluation five regions were defined: scull, spine including the pelvis, femora, humeri and ribs including scapulae and sternum. Results: In 9/20 patients neither with SZ nor with MRI bone metastases were detected (staging M0). Among the remaining 11 patients SZ detected 109 and MRI 150 lesions which were typical for bone metastases. All of these 11 patients were staged Ml correspondingly with both methods. Within the thorax (ribs, sternum, scapulae) MRI discovered only 6/17 and within the scull 0/6 lesions which were suspicious for metastases in SZ. Inversely MRI identified much more metastatic lesions than SZ within the femora (20/16), the humeri (14/12) and the spine including the pelvis (110/58). Conclusions: Susceptibility-, truncation*, chemical-shift-, third arm- and particularly pulsation artifacts along with the impossibility to chose slice orientation equally advantageous for all regions of the body cause impaired image quality of MRI whole body scanning. Therefore, concerning the detection rate of bone metastases within the thorax (ribs, sternum and scapulae) and the scull, conventional Turbo-STIR-MRI whole-body scans are even less accurate than conventional planar bone scintigraphy in those regions.

scholarly journals Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients

2021 ◽  
Author(s):  
Nils Martin Bruckmann ◽  
Julian Kirchner ◽  
Lale Umutlu ◽  
Wolfgang Peter Fendler ◽  
Robert Seifert ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Bone Scintigraphy ◽  
Fdg Pet ◽  
Primary Breast Cancer ◽  
Whole Body ◽  
Newly Diagnosed ◽  
Breast Cancer Patients ◽  
Initial Staging

Abstract Objectives To compare the diagnostic performance of [18F]FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients. Material and methods A cohort of 154 therapy-naive patients with newly diagnosed, histopathologically proven breast cancer was enrolled in this study prospectively. All patients underwent a whole-body [18F]FDG PET/MRI, computed tomography (CT) scan, and a bone scintigraphy prior to therapy. All datasets were evaluated regarding the presence of bone metastases. McNemar χ2 test was performed to compare sensitivity and specificity between the modalities. Results Forty-one bone metastases were present in 7/154 patients (4.5%). Both [18F]FDG PET/MRI and MRI alone were able to detect all of the patients with histopathologically proven bone metastases (sensitivity 100%; specificity 100%) and did not miss any of the 41 malignant lesions (sensitivity 100%). CT detected 5/7 patients (sensitivity 71.4%; specificity 98.6%) and 23/41 lesions (sensitivity 56.1%). Bone scintigraphy detected only 2/7 patients (sensitivity 28.6%) and 15/41 lesions (sensitivity 36.6%). Furthermore, CT and scintigraphy led to false-positive findings of bone metastases in 2 patients and in 1 patient, respectively. The sensitivity of PET/MRI and MRI alone was significantly better compared with CT (p < 0.01, difference 43.9%) and bone scintigraphy (p < 0.01, difference 63.4%). Conclusion [18F]FDG PET/MRI and MRI are significantly better than CT or bone scintigraphy for the detection of bone metastases in patients with newly diagnosed breast cancer. Both CT and bone scintigraphy show a substantially limited sensitivity in detection of bone metastases. Key Points • [18F]FDG PET/MRI and MRI alone are significantly superior to CT and bone scintigraphy for the detection of bone metastases in patients with newly diagnosed breast cancer. • Radiation-free whole-body MRI might serve as modality of choice in detection of bone metastases in breast cancer patients.

Region of Interest Localization for Bone Age Estimation Using Whole-Body Bone Scintigraphy

2021 ◽  
Vol 10 (2) ◽  
pp. 22-29
Author(s):  
Thanh-Cong Do ◽  
Hyung Jeong Yang ◽  
Soo Hyung Kim ◽  
Guee Sang Lee ◽  
Sae Ryung Kang ◽  
...  
Keyword(s):  
Bone Scintigraphy ◽  
Age Estimation ◽  
Region Of Interest ◽  
Bone Age ◽  
Whole Body ◽  
Body Bone

scholarly journals Kezdeti tapasztalatok a 99mTc-PSMA-SPECT/CT-vel prosztatarákos betegekben

2018 ◽  
Vol 159 (35) ◽  
pp. 1433-1440
Author(s):  
István Farkas ◽  
Zsuzsanna Besenyi ◽  
Anikó Maráz ◽  
Zoltán Bajory ◽  
András Palkó ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Bone Scintigraphy ◽  
Transmembrane Protein ◽  
Tracer Uptake ◽  
Whole Body ◽  
Primary Prostate Cancer ◽  
Cancer Tumor ◽  
Visceral Metastases ◽  
Male Patients

Abstract: Introduction: The prostate-specific membrane antigen (PSMA) is a transmembrane protein, that is highly expressed on the surface of prostate cancer cells. In the last few years, several PSMA-specific ligands have been developed, that can be successfully used to detect primary prostate cancer, tumor recurrences and metastases as well. Aim: The goal of our work was to examine the clinical application of a 99mtechnetium-labeled PSMA-radiopharmaceutical as part of the routine diagnostics of prostate cancer. Method: We examined 15 male patients with verified prostate adenocarcinoma with suspicion of progression or recurrence of the disease. We performed whole-body PSMA-SPECT/CTs and multiparametric MRIs of the prostate and the pelvic regions within a week. We used 99mTc-mas3-y-nal-k(Sub-KuE) for the PSMA-SPECT scans. The images were visually evaluated by independent observers. The results were compared with the follow-up bone scintigraphies as well. Results: Twenty-two PSMA-positive lesions were found. Nine of them were localized outside, 13 were within the MRI’s field of view. From these 13 lesions, 7 matched with the SPECT/CT results and in 5 cases the MRI images showed no abnormalities. In one case, bone metastasis was suspected on the MRI scan but there was no corresponding pathological tracer uptake on the SPECT images. In two patients, none of the examinations showed signs of prostate malignancy. Four patients had PSMA-positive bone metastases. One of them had a matching PSMA/SPECT and bone scintigraphy result and in one case the PSMA examination showed metastasis in contrast to the negative bone scintigraphy. Conclusion: PSMA-SPECT/CT with 99mTc-mas3-y-nal-k(Sub-KuE) is a promising diagnostic tool. This technique is capable of visualizing bone metastases and it can detect local recurrences and visceral metastases as well. Orv Hetil. 2018; 159(35): 1433–1440.

Sign in / Sign up

Export Citation Format

Share Document